CytoMed Therapeutics Limited/$GDTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Ticker
$GDTC
Sector
Primary listing
Employees
42
Headquarters
Singapore, Singapore
Website
GDTC Metrics
BasicAdvanced
$13m
-
-$0.27
-0.17
-
Price and volume
Market cap
$13m
Beta
-0.17
52-week high
$3.68
52-week low
$0.68
Average daily volume
28k
Financial strength
Current ratio
5.165
Quick ratio
3.141
Long term debt to equity
6.159
Total debt to equity
7.041
Interest coverage (TTM)
-202.49%
Profitability
EBITDA (TTM)
-2.992
Gross margin (TTM)
89.57%
Net profit margin (TTM)
-462.39%
Operating margin (TTM)
-491.79%
Revenue per employee (TTM)
$15,540
Management effectiveness
Return on assets (TTM)
-29.31%
Return on equity (TTM)
-50.28%
Valuation
Price to revenue (TTM)
18.8
Price to book
1.95
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
-3.678
Free cash flow yield (TTM)
-27.19%
Free cash flow per share (TTM)
-0.294
Growth
Revenue change (TTM)
71.02%
Earnings per share change (TTM)
56.70%
3-year revenue growth (CAGR)
33.24%
3-year earnings per share growth (CAGR)
-4.76%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs